Study why some people with eczema get more severe
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at why disease tends to be more severe in some people with atopic dermatitis (eczema), especially those with a specific genetic change in the IL-4 receptor (IL-4Ra). The results may help explain what drives flare-ups and could guide better treatments in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 65 years old
- You must have atopic dermatitis (eczema) that meets standard diagnostic rules
- You cannot be enrolled in another clinical trial at the same time
- No immune-suppressing or immune-changing medicines in the last 4 weeks (like certain steroids, methotrexate, or JAK inhibitors)
- No eczema treatments right before the study that are specifically restricted (including bleach baths in the last 7 days, and certain skin creams in the last 7 days)
- You should not have certain infections or immune problems (like HIV/hepatitis/tuberculosis) or major medical illnesses that could affect safety
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether removing a type of bacteria (staph) from the skin can reduce the severity of atopic dermatitis (eczema). It may help people with moderate to severe eczema who have not used certain treatments recently.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
This study uses special imaging to look at the structure of skin, comparing people with eczema (who have used steroid creams) to healthy volunteers. Researchers want to understand how the skin changes with eczema and its treatment.
This observational study follows people with eczema (atopic dermatitis) and sometimes related allergies over time, even if they keep their usual medical treatments. It may help researchers better understand how these conditions change and what factors relate to symptoms.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This study compares two types of eczema treatments—upadacitinib and biologics—to see how well they help adults with moderate-to-severe atopic dermatitis achieve minimal disease activity. It may help you understand which treatment option could work best for your eczema.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.